Berlin, Germany – Maintaining stable blood pressure during major surgery is a cornerstone of patient care, but the optimal approach remains a subject of intense debate. Recent research, building on the landmark IMPROVE-multi trial, suggests that simply targeting a specific mean arterial pressure (MAP) – the average pressure in your arteries during a heartbeat – isn’t necessarily the answer. Instead, a more nuanced understanding of *why* a patient’s blood pressure is dropping and tailoring treatment accordingly, may be crucial for improving outcomes after surgery. This is particularly relevant for patients undergoing major abdominal surgery, a group considered at high risk for post-operative complications.
The discussion stems from a letter responding to the IMPROVE-multi trial, published in JAMA, which found that individualizing blood pressure management based on a patient’s typical nighttime MAP didn’t lead to better results than maintaining a MAP of 65 mm Hg or higher. Although the trial didn’t demonstrate a clear benefit to the individualized approach, experts emphasize that maintaining blood pressure with vasopressors – medications that constrict blood vessels – doesn’t automatically guarantee adequate blood flow to vital organs. This highlights a critical point: blood pressure is a vital sign, but it’s not the whole story.
The Complexity of Intraoperative Hypotension
Intraoperative hypotension, or low blood pressure during surgery, is a common occurrence. It’s similarly linked to a higher risk of organ injury, including acute kidney injury and myocardial injury. Still, the causes of this drop in blood pressure are varied. As anesthesiologists recognize, hypotension can stem from several factors, including vasodilation (widening of blood vessels), insufficient blood volume (hypovolemia), a slow heart rate (bradycardia), or a weakened heart muscle (myocardial depression). The response to the IMPROVE-multi trial underscores that addressing the *underlying cause* of the hypotension is paramount, rather than simply raising the blood pressure with medication.
“From a pathophysiologic perspective, hypotension should thus be specifically treated with vasopressors, fluids, chronotropic agents, or inotropes to directly address the underlying cause(s)—and not always with vasopressors,” the authors explain. This means a patient experiencing hypotension due to blood loss will require fluids, while one with a slow heart rate might need medication to increase their heart rate. A blanket approach, focusing solely on achieving a target MAP, may miss the root of the problem.
IMPROVE-Multi and the Search for Better Strategies
The IMPROVE-multi trial, a large randomized controlled trial conducted across 15 German university hospitals between February 2023 and April 2024, enrolled 1272 patients undergoing major abdominal surgery. The study aimed to determine whether individualized blood pressure management, based on preoperative nighttime MAP measurements, improved clinical outcomes compared to a standard approach of maintaining a MAP of 65 mm Hg or higher. The trial found no significant difference in the incidence of a composite outcome of acute kidney injury, acute myocardial injury, nonfatal cardiac arrest, or death within the first seven days after surgery between the two groups. 1134 patients were included in the primary analysis, with a median age of 66 years.
Despite the lack of a clear benefit in the IMPROVE-multi trial, researchers aren’t abandoning the idea of personalized blood pressure management. Critical Care Reviews highlights that the trial was a “landmark pragmatic RCT” because it rigorously tested a scalable individualized strategy. The finding that achieving better MAP metrics doesn’t automatically translate to improved clinical outcomes doesn’t negate the importance of optimizing blood pressure; it simply suggests that the current approach may be too simplistic.
Beyond Blood Pressure: The Need for Comprehensive Monitoring
One limitation of the IMPROVE-multi trial, as acknowledged in the response, was its focus solely on blood pressure. The trial did not systematically monitor variables like stroke volume and cardiac output – measures of how much blood the heart is pumping – which provide a more complete picture of a patient’s circulatory function. Understanding these parameters could facilitate clinicians identify specific “hypotension endotypes,” or distinct patterns of low blood pressure, and tailor treatment accordingly.
For example, a patient with low blood pressure and low cardiac output might require inotropic support to strengthen heart contractions, while a patient with low blood pressure and high cardiac output might benefit from vasopressors to constrict blood vessels. Future research should investigate whether blood pressure management based on these distinct endotypes can help prevent organ injury.
The Role of Vasopressors and Potential Risks
While vasopressors are often used to raise blood pressure during surgery, it’s critical to recognize that they aren’t without risks. The authors of the response note that vasopressors themselves can be associated with acute kidney injury. This underscores the need for careful consideration of the potential benefits and risks of vasopressor utilize, and a focus on identifying and addressing the underlying cause of hypotension whenever possible.
The choice of vasopressor also matters. Different vasopressors have different mechanisms of action and side effect profiles. Anesthesiologists must carefully select the appropriate vasopressor based on the patient’s individual circumstances and the underlying cause of their hypotension.
What Does This Mean for Patients?
The findings from the IMPROVE-multi trial and the subsequent discussion emphasize the importance of a collaborative approach to perioperative care. Patients undergoing major surgery should discuss their medical history and risk factors with their anesthesiologist. This will help the anesthesiologist develop a personalized plan for blood pressure management that takes into account the patient’s individual needs.
While the optimal strategy for managing blood pressure during surgery remains an area of active research, the current evidence suggests that a one-size-fits-all approach is unlikely to be effective. A more nuanced understanding of the underlying causes of hypotension, combined with comprehensive monitoring of circulatory function, is essential for improving outcomes after surgery.
Key Takeaways
- Individualizing blood pressure management based solely on preoperative nighttime MAP did not improve outcomes in the IMPROVE-multi trial.
- Addressing the underlying cause of intraoperative hypotension – whether it’s blood loss, a slow heart rate, or a weakened heart muscle – is crucial.
- Monitoring variables beyond blood pressure, such as stroke volume and cardiac output, may help identify specific “hypotension endotypes” and guide treatment.
- Vasopressors, while often used to raise blood pressure, can have risks and should be used judiciously.
Further research is needed to determine whether blood pressure management based on distinct hypotension endotypes can help avoid organ injury. The ongoing investigation into personalized perioperative care promises to refine surgical practices and ultimately improve patient safety, and recovery. The next step will be analyzing data from ongoing trials that incorporate more comprehensive hemodynamic monitoring to better understand the relationship between blood flow and patient outcomes.
Do you have questions about perioperative blood pressure management? Share your thoughts and experiences in the comments below. And please, share this article with anyone who might find it helpful.
Related reading